Category Archives: Life Extension

While emphasizing safety, innovation, and partnerships at the Dubai Airshow, Boeings senior leaders said the company is focused on returningthe 737 Max to service and supporting customers and supplier partners affected by the airplanes grounding, while they also expressed empathy for those most affected by the two fatal crashes of the aircraft.

Our thoughts remain with families and victims, and we continue to support them economically and emotionally, said Stan Deal, president and CEO, Boeing Commerical Airplanes, at a briefing yesterday. All employees at Boeing have them in their thoughts, and we will use these tragedies to refocus on safety, quality, and integrity.

Leanne Caret, president and CEO of Boeing Defense, Space & Security, and Ted Colbert, president and CEO of Boeing Global Services, voiced similar sentiments.

Turning to other programs, Deal said the in-development 777X will fly in early 2020, and we plan to deliver the airplane in the early 2021 timeframe, slightly later than originally hoped. Meanwhile, the company has a backlog of more than 5,500 commercial aircraft, and with global demand forecast for more than 44,000 airliners over the next 20 years at an estimated value of $16 trillion, the fundamentals remain in place for strong growth, Deal said.

Caret notedBoeing projects $2.5 trillion in defense and space market opportunities over the next decade and is continuing to see demand from the U.S. and partners around the world, with a significant portion coming from the Middle East. Caret cited the KC-46 Pegasus aerial refueling tanker, the new T-7 jet trainer, and the CH-47F Chinook and AH-64 Apache military helicopters as ideally suited to Middle East customers.

Boeing is also the prime contractor for the International Space Station, and Caret congratulated the UAE Space Agency and astronaut Hazzaa Al Mansoorion his recent mission to the space station.

With less than 20 percent of the worlds military aircraft fleet slated for replacement over the next decade, Boeing also sees substantial demand for upgrades, maintenance, and service life extension programs, creating large opportunities for its Global Services division.

"The strength of Boeing is our unrivaled ability to deliver lifecycle value for our customers," Colbert said.

Boeing estimates global demand for $225 billion in commercial and government services over the next decade, with the Middle East ranking fourth in global aftermarket growth behind the U.S., Europe, and Asia-Pacific.

Colbert said that Boeing maintains two parts hubs in Dubai that stock some 1.7 million parts to support customers. With big data analytics expected to play a growing role in predictive maintenance and other aftermarket services, Boeing has been operating a digital analytics hub in the UAE since 2007, although its been used primarily for flight planning services through its Jeppesen division.

Read this article:

Boeing Focused on Maxs Safe Return to Service - Aviation International News

Until now, the Dietary Guidelines for Americans has provided dietary advice for people 2 years and older, prompting caregivers and healthcare practitioners to turn to a disparate set of resources to figure out the best diet for pregnant women, infants and young children. These include famous books, such as What to Expect When Youre Expecting, and guidelines from various organizations, such as the American Heart Association and the American Academy of Pediatrics.

And while these are influential and well-researched recommendations, by bringing this group under the purview of the broader Dietary Guidelines for Americans, the US government will for the first time take ownership of them a move that will provide a consistency that so far has been lacking.

The move also is a double-edged sword for the CPG industry. Some hope that including this group in the broader Dietary Guidelines for Americans will protect them undue corporate influence, while others see potential opportunities for innovative manufacturers creating solutions to help Americans meet the recommendations.

While we wont know for sure what the guidelines will include until the recommendations are released and vetted, this episode of FoodNavigator-USAs Soup-To-Nuts podcast explores some of the themes, suggestions and questions that dietitians and industry players would like to see addressed and how these issues might impact CPG manufacturers.

[Editors Note: Never miss another episode of FoodNavigator-USAs Soup-To-Nuts Podcast subscribe to us on iTunes.]

Even though the Dietary Guidelines for Americans are designed with health care professionals in mind and, therefore, are not very consumer-friendly, Amy Kimerlain, a registered dietitian who specializes in childrens nutrition and a spokeswoman for the Academy of Nutrition and Dietetics, explained at the Food & Nutrition Conference & Expo in Philadelphia last month that the inclusion of recommendations for the first 1,000 days of life is a critical first step to improving the lives of women and children in the US.

The dietary guidelines allow for general recommendations for healthy Americans across the population, and so now with the introduction of looking at the first 1,000 days, were obviously going to pay closer attention to now not only infants and toddlers, but also prenatally as well, Kimerlain said. She added, these guidelines ultimately will allow for people to look and reflect to see what changes they may need to make in order to improve their health over the long run.

With that in mind, Kimerlain said she hopes the recommendations look not only at the nutrients that are critical to a childs development, but also on what and how much pregnant women need to consume to keep themselves healthy. This includes advice around how many extra calories do women actually need when eating for two, guidance on how much weight they should expect to gain and remain healthy and how diet can help manage potential complications.

Drilling deeper into what the guidelines might include for expecting women, Kristi King who is also a spokeswoman for the Academy of Nutrition and Dietetics and the senior pediatric dietitian at Texas Childrens Hospital in Houston, says she hopes the guidelines will include specific recommendations about choline intake.

She explained that choline is a underrated nutrient, that were just now starting to figure out that within that first 1,000 days is so incredibly important for infants and brain development.

She added that this could be an opportunity for supplement manufacturers as well as select food marketers.

An early mover on this from the supplement side is Life Extension, which is a Fort Lauderdale, Fla., based company that launched at FNCE its Prenatal Advantage multivitamin. Like most other prenatal supplements, Life Extensions Prenatal Advantage includes folic acid and DHA, which have long been recognized as essential for developing infants. But it also is one of the few prenatal supplements that includes choline.

On the food side, one of the best sources of choline are eggs, one of which provides 25% of the recommended daily value.

Mickey Rubin, the executive director of the American Egg Boards Egg Nutrition Center explained the importance of the eggs in providing choline as well as more generally supporting maternal and infant health.

Despite the importance of choline to developing infants, he noted only about 25% of expecting mothers are familiar with it, compared to 90% who know about folic acid. In addition, little more than half of health professionals currently are aware of choline.

Beyond choline, Rubin says the high amount of lutein in eggs also can help support developing infants cognitive development by increasing their macular pigment which has been linked to cognition.

Fiber is another necessary nutrient for expecting mothers, infants and young children that King says she wants the upcoming dietary guidelines to highlight. Not only does she say she wants to see stronger recommendations around how much should be consumed, but also guidance clarifying how best to get it including, of course, fresh fruits and vegetables, but also canned and frozen produce as well.

Related to fiber and gut health, King says she would also like to see in the recommendations advice around probiotics, including if they are appropriate for children and expecting women and if so which ones and how much.

Scientifically-based guidance in the dietary guideline recommendations around breastfeeding versus the use of formula also likely will have a significant impact on the CPG industry, predicts King.

Like many dietitians, King advocates that breastfeeding is best, but also acknowledges it is not always an option. In those cases, she says, she would like to see the dietary guidelines recommend the use of FDA approved formula, which is held to a higher safety and nutrition standard than many others from around of the world.

In addition to addressing infant formula, King predicts, the recommendations will tackle toddler milks, for which there is not the same nutritional standard as infant formula but about which much confusion and controversy swirl.

Beverages more broadly also will likely be a hot button topic in the recommendations, with experts predicting the dietary guidelines will call for significantly reduced consumption of sugary drinks, potentially including juice. It likely also will expand or include recent guidelines to restrict drinks for children under five to breast milk, water and dairy milk with only occasional consumption of 100% fruit juice if whole fruit is not an option.

These likely are only a small sample of the issues that will be addressed in the guidance. While the upcoming guidance likely wont make everyone happy or be perfect, as Kimerlain notes, it is a first step.

Continued here:

Soup-To-Nuts Podcast: What might the 2020 dietary guidelines for the first 1,000 days include? - FoodNavigator-USA.com

A new report entitled Global Soy Isoflavones Markets was recently added to the CMFE Insights database. It has allowed marketers to understand the key attributes that can help investors capitalize effectively on market dynamics, providing a market definition, product description, competitor analysis, and more.

The bulk of the report also includes the market definition, the commercial division, the examples and the difficulties that affect the market, as well as the investigation of the fundamental factors that govern the market. The survey also shows global segmentation by aggregating production, capacity, contact data, costs and revenues of key players. The industry review was conducted using Porters five forces and SWOT analysis. The report consists of a qualitative and quantitative analysis of current trends, product characteristics, end-product applications, end-users and other industry sectors.

Get sample Copy: https://www.cmfeinsights.com/request-sample.php?id=114777

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

Demand Coverage (Market Size & Forecast, Consumer Distribution):

Company Coverage (Sales data, Main Products & Services etc.):

Major Region Market

Avail the maximum discount @ https://www.cmfeinsights.com/ask-for-discount.php?id=114777

Table of Content:

Global Soy Isoflavones Market Research Report 2019

Chapter 1 Soy Isoflavones Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 to be continue.

Address:

Office 271

321 323 High Rd

Chadwell Heath

RM6 6AX UK

Contact Us:

Email: sales@cmfeinsights.com

Call us: +44-7537-121342

Read more:

Future analysis and scope of Soy Isoflavones Market by 2019 to 2025 | leading Companies- NOW Foods, InVite Health, ADM, DHC, GNC and Life Extension -...

Twelve days removed from Willie Taggart getting fired with a 9-12 record at Florida State, 8-13 Scott Frost got a 2-year extension at Nebraska.

Two programs in different places made completely different decisions on the future of their respective head coaches. One didnt believe in the vision, the other bought in even more.

On the surface, it evokes an interesting discussion as to why certain coaches have more leverage than others. Some will use that as a reason to question why Frost got an extension, especially considering how underwhelming 2019 has been. For starters, different people are making that decision.

Lets pick the brain of the person who did make that decision on the Nebraska side, athletic director Bill Moos.

He was pretty candid about that decision when it was announced before Saturdays game against Wisconsin:

Do you speak athletic director? Dont worry, I do. Id be happy to translate that quote for you.

We gave him the extension because we were desperate for some momentum going into the home stretch of the recruiting cycle.

That, in my opinion, is at the forefront of a decision like that.

Nebraska entered the day at No. 33 in the 2020 class rankings (247sports). Thats roughly 5 weeks out from the Early Signing Period. Thats behind the likes of Northwestern, Iowa, Wisconsin, Purdue and just 1 spot ahead of Minnesota. The Huskers have just 13 verbal commits. Only Rutgers and Illinois have fewer total commits than Frosts program.

You dont need me to translate that. Thats not great for Frosts third recruiting class. Thats why in his mid-week press conference, Frost was asked about the on-field struggles carrying over to the teams recruiting.

People see where this is going and were not going to lose sight of that, Frost said, in a video captured by Matt Reynoldson of KLKN. This group has done an unbelievable job of getting the program turned. Its certainly not happening as fast as I want it to. But were gonna get it done. Thats why Im here. [We] knew this thing wasnt in great shape when we took it over and we knew we had a lot of things to fix. Were in the process of doing that.

I think theres a tremendous opportunity for recruits to come in and try to make an impact early. That vision and opportunity is going to help us on the recruiting trail a lot.

Combine that with the ESPN story that came out this week that quoted Tom Osborne saying he thinks Frost feels the weight of this thing.

That explains the timing. As Moos said, he planned on doing it anyway. He picked Saturday morning ahead of a 3-game stretch to end the season in which Nebraska had matchups against Wisconsin and Iowa, both of whom are teams currently ranked in the Top 25. If Frost cant win his first game against a ranked foe at Nebraska, the Huskers will spend bowl season at home for the third straight year.

You bet Moos wanted to make sure Nebraska wanted to get some offseason momentum.

So theres another question that many are probably asking, and understandably so Frost wasnt going anywhere so why did the Huskers compete against themselves with the extension? Its a fair question.

Its one that The Athletics Andy Staples threw out there:

(Andy and I actually had a bit of a back and forth about it. You can see that exchange here.)

Recruiting is a fickle business. Negative recruiting happens everywhere.

If Im a B1G West coach and I know a kid is strongly considering Nebraska, Im telling him sure, Frost is under contract. But do you really think that fanbase with those expectations are going to give Frost 5 years?

Its easy to convince people that a coach is on the proverbial hot seat, even if Nebraska fans would sooner give up Runza for life than they would bail on Frost. The last thing Nebraska wants is a recruit even thinking about wait, could Frost be on the hot seat by the time Im a sophomore?

By extending Frost, thats not in question. Instead, he can walk into any living room for the next month and say, I started off 8-13 and they still gave me a 2-year deal. The administration has my back. They have patience. Come be a part of a program on the rise and I promise you wont be hung out to dry.

If Frost wants to use that pitch, Im on PayPal.

I know what you might be thinking that might make sense in theory, but didnt Nebraska just become more financially committed to Frost just in hopes of finishing the recruiting cycle strong?

Yes and no. We dont know the buyout numbers of the new deal just yet, but if thats still relatively unchanged, not much will change in terms of the financial commitment. Frost isnt going to simply coach out the remainder of his contract on his current deal. Athletic directors never do that anymore because of the recruiting impact. Theres no such thing as a lame-duck coach. Why? Its too easy to negatively recruit against a lame-duck coach.

From an ADs standpoint, Moos knows his tenure is going to be defined by the Frost hire. If Frost fails, his job is on the line, too. He wont even be around to deal with the ramifications of that buyout. Thats why it might be viewed as hedging to be anything but aggressive with Frosts contract.

So now, we know more than ever that Moos is all in with Frost. There wasnt ever any doubt of that. While the results havent been what he hoped for yet, theres logic behind a move that some mightve waited to make.

Its Frost or bust for Nebraska, just as we always thought.

See the article here:

Some thoughts on Scott Frosts extension: Why now, and what it means - Saturday Tradition

The Lead

As Canadas fleet continues to age, the availability for vessels to take on major projects is becoming scarce. This fall, an oceanographic survey with the goal of monitoring climate change was cancelled by Fisheries and Oceans Canada because there were no vessels available to take on Atlantic waters. Hudson, the Canadian Coast Guard science ship, is regularly tasked with working on the offshore Atlantic Zone Monitoring Program (AZMP) but was not able to because it had not had its life extension check completed.

Similarly, Coriolis II, a private research vessel brought on by Fisheries and Oceans Canada for 2019, has been considered unable to participate in the Maritimes region survey, according to Robin Jahn, representative for Fisheries and Oceans Canada.

The oceanographic survey is tasked with collecting and analyzing physical, chemical and biological data from Canadas East Coast in order to evaluate the changes that the ocean is experiencing. Dave Hebert, a research scientist with Fisheries and Oceans Canada, said that one of the issues is to determine whether or not its a long-term trend or just year-to-year variability.

AZMP has never been cancelled before, and one of the many outcomes of this will be the loss of half a year of plankton sampling, which will distort the results of year-to-year data collection says CBC News.

Internationally

The international oil industry continues to be burdened by the heightened trade conflict between the U.S. and China this year.

At an energy conference in Abu Dhabi this week, the Organization of the Petroleum Exporting Countries (OPEC) secretary general Mohammad Barkindo stated that smoothing out a trade deal between the U.S. and China will almost remove that dark cloud that had engulfed the global economy, according to The Globe and Mail.

Next month, OPEC+, which includes the Organization of the Petroleum Exporting Countries and its allies such as Russia, is scheduled to meet and discuss the cutbacks that were made to oil production this past January to balance supply and demand. According to UAE Energy Minister Suhail al-Mazrouei, slashes made to oil output have done what they were supposed to do and have resulted in more stable prices.

In Canada

Developing a floating liquefied natural gas facility off the coast of B.C. is on the horizon for Rockies LNG Partners, a coalition of Canadian natural gas producers comprised of companies such as Peyto Exploration & Development Corp., and Advantage Oil & Gas Ltd. According to Chief Executive Officer Greg Kist of Rockies LNG, floating barges would have a significantly smaller environmental impact.

Kist explained that in Northern British Columbia, there are limited flat pieces of land, so if you could remove significant cost and impact associated with trying to flatten a piece of land, we think that thats a much better outcome than land-based facilities. He said that the only land-based infrastructure required would be a control room, jetty structures and bunking for workers because the LNG equipment would be on a facility based on the water.

Three barges would be needed for the project that the Rockies LNG Partners are considering, which is estimated to produce 12 million tons of natural gas a year, Bloomberg reported. The partnership hopes to find a project site at the beginning of 2020 and aims to have the project up and running by 2026.

Noteworthy

West of the oilsands, another sector suffers its own existential crisis (The Financial Post)

Nine oil companies to watch during the green energy push (The Globe and Mail)

TSX futures slip after Trump threatens to increase tariffs (Reuters)

Saudis Are Urged Not to Miss the Train on Aramco IPO (The Wall Street Journal)

Venice partly submerged by highest tides in half a century (The Washington Post)

India says it plans to use hydrogen-based fuel to tackle air crisis (The Guardian)

The climate chain reaction that threatens the heart of the Pacific (The Washington Post)

Air pollution nanoparticles linked to brain cancer for first time (The Guardian)

In Opinion

In an effort to mitigate domestic emissions, countries such as the U.S. have been exporting their carbon footprint, sending dirtier energy production methods like coal abroad. Joe Oliver, previously federal minister of finance in 2014 and 2015, claims that the substitution effect should be considered when analyzing the problem of global carbon leakage.

Oliver explained that if Canada started expanding pipeline infrastructure to its coasts, the countrys oil and gas supply would be able to reach international markets in Europe and Asia. He said that although this would increase Canadas emissions, more exportation would allow countries to stop being so reliant on coal and would reduce the global emission footprint altogether.

There is a disconnect between an allegedly existential threat of global warming and policies that are ineffective and frequently undermine green goals, said Oliver in his column in Financial Post. He believes that this disconnect will continue to grow until Canada recognizes that building pipelines will actually reduce global GHG emissions.

More from iPolitics

Visit link:

The Drilldown: Floating barges on the horizon for Rockies LNG Partners - iPolitics.ca

By Katie PrattUniversity of Kentucky

The University of Kentucky Cooperative Extension Service recently received more than $1 million to help further the organizations statewide educational efforts in opioid prevention and recovery.

The grant from the Substance Abuse and Mental Health Services Administration will allow Cooperative Extension Service professionals to implement new programming efforts in south central and Western Kentucky during the next two years.

The two-year grant will allow extension to bring new and innovative programs to the state and build upon its already successful efforts. Photo by Darwin Brandis, Getty Images.

Kentuckians said substance use and its related effects was the most significant issue facing the commonwealth today in extensions recently released community assessment survey. This grant will help us aggressively address this issue, and help set communities on the path to recovery, said Alison Davis, project lead and director of UKs Community Economic Development Initiative.

Many of the programs in this grant will continue to build on UK Cooperative Extensions existing efforts to reduce opioid use and aid in recovery efforts across the state. Extension already has successful programs in place that teach gardening, nutrition and life skills education to those recovering from substance use addiction and support programs for families with a loved one with a substance use disorder.

The Kentucky Cooperative Extension Service is currently recognized as a leader among the land-grant university system for outreach efforts targeting substance use prevention and recovery, said Jennifer Hunter, assistant director for family and consumer sciences extension and one of the co-leaders on the grant. We are excited to be able to continue to expand our educational efforts and enhance the level of resources available at the community level.

As part of the grant, extension will offer an Addiction 101 course geared toward health care workers, extension agents and community leaders. The program will talk about the science behind addiction including genetic and hereditary risk factors for developing an addiction disorder.

Alex Elswick, UK extension specialist for substance use prevention and recovery, will lead the program.

We want to remove the stigmas associated with addiction, so health care workers and community members feel more comfortable and equipped to help those struggling with opioid use addiction and recovery, he said.

Extension personnel will also offer Botvin LifeSkills Training, which is a national, evidence-based substance abuse prevention program, to area middle school students.

Melissa Bond, program leader for UKs Arts Extension program, will partner with the UK College of Fine Arts to lead the arts expression component of the grant. This component will give individuals, families and communities a healthy, therapeutic outlet to express their feelings of anger and sadness with substance use addiction.

Financial issues tend to plague those recovering from a substance use disorder and can be a cause of subsequent relapses. To help these individuals, extension will expand their release of a financial education curriculum developed by Elswick and Kelly May, UK senior extension associate.

The curriculum, Recovering your Finances, specifically addresses financial issues those in recovery may face and guidance for overcoming those obstacles.

It is being piloted in Mercer County this fall and will also be offered in Boyd, Bourbon, Knox and Leslie counties through a grant UK received from the U.S. Department of Agricultures Rural Community Development Initiative.

Extension will also continue to offer support to local community health coalitions who are addressing substance use prevention and recovery.

UK College of Agriculture, Food and Environment, through its land-grant mission, reaches across the Commonwealth with teaching, research and extension to enhance the lives of Kentuckians.

View original post here:

Grant will help UK Cooperative Extension Service expand opioid prevention and recovery efforts - User-generated content

In an update to Saugeen Shores councillors Nov. 11, Christopher Mercanti, Bruce Power's Manager of Community and Indigenous Relations, said when the Major Component Replacement program begins in January there will be an immediate need for 500-plus additional workers.

When Bruce Power begins the $13 billion private investment Major Component Replacement (MCR) program in January, a good 500- plus people will be needed immediately according to Christopher Mercanti, Bruce Powers Manager of Community and Indigenous Relations in a Nov. 11 update to Saugeen Shores councillors.

Bruce Power said the MCR, a $13 billion private investment in the Life Extension program, will create and sustain 22,000 direct and indirect jobs annually, and inject $4 billion into the Ontario economy.

Saugeen Shores Coun. Jami Smith, a Bruce Power Corporate Services employee, said they are looking forward to welcoming the new workers, and asked when the peak demand for labour may be..

Mercanti, counting down 66 days to the MCR, said in January there will be several hundred more workers on site doing prep work, but the real influx doesnt really start until next spring into next summer 2020 he said, adding there would be at least 500 more people on site immediately when they start in January.

Mercanti said continued improvements in operational performance included a record-setting 361 of continuous operation for Unit 1, additional megawatt production, and a historic agreement with Saugeen Ojibway Nation (SON) to collaborate to market medical isotopes.

This medical isotope is used in the treatment of prostrate cancer, and were looking at other isotopes that can be exposed to our neutron fields, and get to market and help treat others cancers such, as breast cancer Mercanti said.

Mercanti said community engagement efforts included awarding 100 Grey-Bruce-Huron students each with $500 scholarships; scholarships to 12 local Indigenous students in partnership with Indspire; the record-setting 6,200 visitors who took the Bruce Power bus tour this past summer; and continued support to Saugeen Memorial Hospital which included $50,000 annually in the past four years; and the Gran Fondo

Saugeen Shores Deputy Mayor Don Matheson thanked Bruce Power for all it does.

The world is an oyster and it is going to open up to us in January with the MCR, so I look forward to all the great wonderful things that will come out of that. he said.

See the original post:

Jobs, cancer-fighting isotopes and nuclear innovation highlight Bruce Power update - Shoreline Beacon

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-treated Participants in the ATTR-ACT Study

Near-complete Stabilization of TTR Maintained in Participants Throughout Duration of Study

Serum TTR levels, a Prognostic Indicator of Survival in ATTR-CM Patients, Were Elevated and Maintained in the Normal Range Throughout the Study Duration

Cardiac Biomarkers and Echocardiographic Parameters Were Stable Throughout Trial Duration

Presentation from AHA 2019 Scientific Sessions Available on Company Websites (eidostx.com and bridgebio.com)

SAN FRANCISCO, Nov. 16, 2019 (GLOBE NEWSWIRE) -- Correction updates the increase in mean serum TTR levels for variant-carrying ATTR-CM to 56% at OLE Visiting Day 180.Corrected release follows in full.

BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO) and Eidos Therapeutics, Inc. (Eidos) (EIDX), today presented positive data from the companies ongoing Open Label Extension (OLE) of the Phase 2 clinical trial studying AG10 in patients with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM). ATTR-CM is a progressive and fatal disease that is an under recognized cause of heart failure. The data were presented in a late-breaking featured science oral presentation at the American Heart Association (AHA) Scientific Sessions in Philadelphia, Pennsylvania.

Study participants received 800mg of AG10 twice daily during the OLE and were followed for a median of 65 weeks since Phase 2 initiation. AG10 treatment was generally well-tolerated and resulted in near-complete TTR stabilization as measured using established ex vivo assays. Lower rates of mortality (death or cardiac transplantation) and cardiovascular-related hospitalizations were observed in AG10 Phase 2 OLE participants than were reported in a similar population of ATTR-CM patients who received placebo for 15 months in the ATTR-ACT study. Cardiac biomarkers and echocardiographic parameters were stable in patients treated with AG10 in the Phase 2 OLE.

This update from our Phase 2 OLE demonstrated continued tolerability of AG10 in patients with advanced ATTR-CM. We also observed meaningfully lower rates of mortality and cardiovascular hospitalizations than what would be expected for untreated ATTR-CM patients with similar disease severity, said Jonathan Fox, M.D., PhD., FACC, president and chief medical officer of Eidos. These encouraging data continue to support the development of AG10 as a potentially best-in-class treatment for ATTR-CM patients.

AG10 Phase 2 Open Label Extension Results

The ongoing OLE study enrolled 47 of 49 participants (96%) from the 28-day randomized, placebo-controlled, Phase 2 study of AG10 in ATTR-CM patients with New York Heart Association (NYHA) Class II or III symptoms. Interim analysis of the ongoing study was completed on August 31, 2019 in conjunction with annual regulatory reporting and review, at which time 41 participants remained in the study. Three (6.4%) participants in the OLE had died, two due to disease progression and one due to cervical cancer. Three (6.4%) additional patients enrolled in the study had discontinued treatment, including one participant who underwent cardiac transplantation for their disease.

The presentation of the Phase 2 open label extension data from the American Heart Association (AHA) Scientific Sessions will be available on the company website (eidostx.com and bridgebio.com).

A Phase 3 study of AG10 in ATTR-CM patients (ATTRibute-CM) is currently ongoing. In Part A of the study, change in six-minute walk distance at 12 months will be compared between active treatment and placebo groups as the first registrational primary endpoint. In Part B, all-cause mortality and frequency of cardiovascular-related hospitalizations will be compared between treatment and control groups at 30 months total duration. In Part B, concomitant use of therapies indicated for the treatment of ATTR-CM may be allowed. The study is enrolling at 44 sites across six countries and enrollment for Part A is now projected to complete in the second half of 2020, with top-line data expected in 2021.

Story continues

About AG10

AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to TTR amyloidosis, or ATTR. In a randomized, placebo-controlled Phase 2 clinical trial in patients with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated greater than 90 percent average TTR stabilization at Day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner. The open label extension of this Phase 2 study identified no safety signals of potential clinical concern associated with administration of AG10 15 months after study initiation. In an exploratory analysis, lower rates of all-cause mortality (including death and cardiac transplantation) and cardiovascular hospitalizations were observed in study participants than in placebo-treated ATTR-CM patients in the ATTR-ACT study. Cardiac biomarkers and echocardiographic parameters were stable in the AG10 Phase 2 OLE.

AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a rescue mutation because co-inheritance has been shown to prevent or ameliorate ATTR in individuals also inheriting a pathogenic, or disease-causing, mutation in the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the stabilizing structure of this rescue mutation.

The Phase 3 ATTRibute-CM study of AG10 in patients with ATTR-CM is underway. Part A of the study will assess the change from baseline in 6-minute walk distance (6MWD) at 12 months. Part B of the study will evaluate reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations at 30 months. In addition, Eidos plans to initiate a Phase 3 study of AG10 in ATTR polyneuropathy (ATTR-PN) in Q1 2020.

About transthyretin amyloidosis (ATTR)

There is significant medical need in transthyretin amyloidosis (ATTR) given the large patient population and limited current standard of care. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into three distinct categories: wild-type ATTR cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM), and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each disease is estimated to be at least 400,000 patients, 40,000 patients and 10,000 patients, respectively.

All three forms of ATTR are progressive and fatal. For patients with untreated ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in life (age 50+), with median survival of three to five years from diagnosis. ATTR-PN either presents in a patient's early 30s or later (age 50+), and results in a median life expectancy of five to ten years from diagnosis for untreated patients. Progression of all forms of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care.

About BridgeBio Pharma

BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBios pipeline of over 15 development programs includes product candidates ranging from early discovery to late-stage development. For more information, please visit http://www.bridgebio.com.

About Eidos Therapeutics

Eidos is a BridgeBio Pharma subsidiary focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing AG10, a potentially disease-modifying therapy for the treatment of ATTR. For more information, please visit http://www.eidostx.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, including the statements about the potential therapeutic and clinical benefits of AG10, the potential for AG10 to be a best-in-class treatment for ATTR-CM patients, the design of our ongoing Phase 3 ATTRibute-CM trial of AG10, our ability to enroll patients in and conduct the ATTRibute-CM trial and our planned Phase 3 clinical trial of AG10 in ATTR-PN in accordance with our plans, our ability to generate data from and to complete these trials, the timing of these events, the indications we intend to pursue and our possible clinical or other business strategies, are forward-looking statements. Forward-looking statements can be identified by terms such as believes, expects, plans, potential, would or similar expressions and the negative of those terms. These forward-looking statements are based on our managements current beliefs and assumptions about future events and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: our limited operating history and historical losses, our liquidity to fund the development of AG10 through current and future milestones, our ability to raise additional funding to complete the development of AG10, our dependence on the success of AG10, our ability to enroll patients in the ATTRibute-CM trial and our planned Phase 3 clinical trial of AG10 in ATTR-PN, results from our clinical trials andpre-clinicalstudies and those of third parties working in the same area as our product candidate, our ability to advance AG10 in clinical development in accordance with our plans, and our dependence on third parties in connection with our manufacturing, clinical trials andpre-clinicalstudies. Additional risks and uncertainties that could affect our future results are included in the section titled Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which is available on the SECs website atwww.sec.govand our websites at eidostx.com and bridgebio.com. Additional information on potential risks will be made available in other filings that we make from time to time with the SEC. In addition, any forward-looking statements contained in this press release are based on assumptions that we believe to be reasonable as of this date. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Media Contact:Grace Rauh917-232-5478Grace.rauh@bridgebio.com

Investor Contact:John GrimaldiBurns McClellan212-213-0006jgrimaldi@burnsmc.com

Read more from the original source:

CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of...

According to Stratistics MRC, the Global Food Emulsifiers Market is accounted for $2.55 Billion in 2017 and is expected to reach $4.48 Billion by 2026 growing at a CAGR of 6.4% from 2017 to 2026. Some of the factors such as growing consumption of convenience foods and premium products, rising beverage industry and high demand for specialty food ingredients in various applications will boost the market growth. However, growing health concerns and Complex US regulatory environment may hinder the market growth.

Emulsifiers used in food are also known as emulgents. Emulsifiers or colloids are extensively used as additives during processing of victuals. These products have a broad application spectrum ranging from bakery to meat processing. The food emulsifier is a substance that stabilizes food emulsion by increasing its kinetic stability. Food emulsifiers are either synthetic or natural food additives, which assist the stabilization and formation of emulsions by reducing surface tension at the oil-water interface.

Request For Report sample @: https://www.trendsmarketresearch.com/report/sample/11330

Amongst Application, Bakery Products segment registered considerable market share during the forecast period due to growing demand for innovative gluten-free baked products. In bread making, they are used for dough conditioning and shelf life extension. By geography, North America dominated the market owing to presence of many international chocolate brands and growing demand for and dairy & frozen desserts and convenience foods among the consumers.

Some of the key players in Food Emulsifiers include Dupont, Cargill Inc.,Corbion , Ingredion Incorporated, Kerry Group Plc,Archer Daniels Midland Company , Lonza Group Ltd.,Danisco A/S, Riken Vitamin Co., Ltd., BASF SE, Palsgaard A/S, Solvay S.A. , Adani Wilmar Ltd.,Stepan Company and Lubrizol Corporation

Types Covered: Mono- & Di-Glycerides and their Derivatives Sorbitan Esters Lecithin Polyglycerol Esters Stearoyl Lactylates Polyhydric Emulsifiers Anionic Emulsifiers Other Types

Functions Covered: Protein Interaction Crystal Modification Lubrication and Processing Aids Starch Complexing Emulsification Oil Structuring Aeration and Stabilization

Sources Covered: Animal Source Plant Source Synthetic

Applications Covered: Dairy & Frozen Desserts Bakery Products Confectionery Products Meat, Poultry, and Seafood Convenience Foods Beverage Oil and Fat Margarine & spreads Infant Formula Sauces & Dressings Food & Nutrition Other Applications

Request For Discount On This Report at:https://www.trendsmarketresearch.com/report/discount/11330

Regions Covered: North Americao USo Canadao Mexico Europeo Germanyo UKo Italyo Franceo Spaino Rest of Europe Asia Pacifico Japano Chinao Indiao Australiao New Zealando South Koreao Rest of Asia Pacific South Americao Argentinao Brazilo Chileo Rest of South America Middle East & Africao Saudi Arabiao UAEo Qataro South Africao Rest of Middle East & Africa

What our report offers: Market share assessments for the regional and country level segments Market share analysis of the top industry players Strategic recommendations for the new entrants Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with detailed strategies, financials, and recent developments Supply chain trends mapping the latest technological advancements

Free Customization Offerings:All the customers of this report will be entitled to receive one of the following free customization options: Company Profilingo Comprehensive profiling of additional market players (up to 3)o SWOT Analysis of key players (up to 3) Regional Segmentationo Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check) Competitive Benchmarkingo Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Browse more detail information about this report visit at:https://www.trendsmarketresearch.com/report/analysis/SMRC/food-emulsifiers-market

Visit link:

Food Emulsifiers Market to Witness Rapid Development During the Period 2017 2026 - Crypto Journal

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-treated Participants in the ATTR-ACT Study

Near-complete Stabilization of TTR Maintained in Participants Throughout Duration of Study

Serum TTR levels, a Prognostic Indicator of Survival in ATTR-CM Patients, Were Elevated and Maintained in the Normal Range Throughout the Study Duration

Cardiac Biomarkers and Echocardiographic Parameters Were Stable Throughout Trial Duration

Presentation from AHA 2019 Scientific Sessions Available on Company Websites (eidostx.com and bridgebio.com)

SAN FRANCISCO, Nov. 16, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (BridgeBio) (NASDAQ:BBIO) and Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), today presented positive data from the companies' ongoing Open Label Extension (OLE) of the Phase 2 clinical trial studying AG10 in patients with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM). ATTR-CM is a progressive and fatal disease that is an under recognized cause of heart failure. The data were presented in a late-breaking featured science oral presentation at the American Heart Association (AHA) Scientific Sessions in Philadelphia, Pennsylvania.

Study participants received 800mg of AG10 twice daily during the OLE and were followed for a median of 65 weeks since Phase 2 initiation. AG10 treatment was generally well-tolerated and resulted in near-complete TTR stabilization as measured using established ex vivo assays. Lower rates of mortality (death or cardiac transplantation) and cardiovascular-related hospitalizations were observed in AG10 Phase 2 OLE participants than were reported in a similar population of ATTR-CM patients who received placebo for 15 months in the ATTR-ACT study. Cardiac biomarkers and echocardiographic parameters were stable in patients treated with AG10 in the Phase 2 OLE.

"This update from our Phase 2 OLE demonstrated continued tolerability of AG10 in patients with advanced ATTR-CM. We also observed meaningfully lower rates of mortality and cardiovascular hospitalizations than what would be expected for untreated ATTR-CM patients with similar disease severity," said Jonathan Fox, M.D., PhD., FACC, president and chief medical officer of Eidos. "These encouraging data continue to support the development of AG10 as a potentially best-in-class treatment for ATTR-CM patients."

AG10 Phase 2 Open Label Extension Results

The ongoing OLE study enrolled 47 of 49 participants (96%) from the 28-day randomized, placebo-controlled, Phase 2 study of AG10 in ATTR-CM patients with New York Heart Association (NYHA) Class II or III symptoms. Interim analysis of the ongoing study was completed on August 31, 2019 in conjunction with annual regulatory reporting and review, at which time 41 participants remained in the study. Three (6.4%) participants in the OLE had died, two due to disease progression and one due to cervical cancer. Three (6.4%) additional patients enrolled in the study had discontinued treatment, including one participant who underwent cardiac transplantation for their disease.

The presentation of the Phase 2 open label extension data from the American Heart Association (AHA) Scientific Sessions will be available on the company website (eidostx.com and bridgebio.com).

A Phase 3 study of AG10 in ATTR-CM patients (ATTRibute-CM) is currently ongoing. In Part A of the study, change in six-minute walk distance at 12 months will be compared between active treatment and placebo groups as the first registrational primary endpoint. In Part B, all-cause mortality and frequency of cardiovascular-related hospitalizations will be compared between treatment and control groups at 30 months total duration. In Part B, concomitant use of therapies indicated for the treatment of ATTR-CM may be allowed. The study is enrolling at 44 sites across six countries and enrollment for Part A is now projected to complete in the second half of 2020, with top-line data expected in 2021.

About AG10

AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to TTR amyloidosis, or ATTR. In a randomized, placebo-controlled Phase 2 clinical trial in patients with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated greater than 90 percent average TTR stabilization at Day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner. The open label extension of this Phase 2 study identified no safety signals of potential clinical concern associated with administration of AG10 15 months after study initiation. In an exploratory analysis, lower rates of all-cause mortality (including death and cardiac transplantation) and cardiovascular hospitalizations were observed in study participants than in placebo-treated ATTR-CM patients in the ATTR-ACT study. Cardiac biomarkers and echocardiographic parameters were stable in the AG10 Phase 2 OLE.

AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a rescue mutation because co-inheritance has been shown to prevent or ameliorate ATTR in individuals also inheriting a pathogenic, or disease-causing, mutation in the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the stabilizing structure of this rescue mutation.

The Phase 3 ATTRibute-CM study of AG10 in patients with ATTR-CM is underway. Part A of the study will assess the change from baseline in 6-minute walk distance (6MWD) at 12 months. Part B of the study will evaluate reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations at 30 months. In addition, Eidos plans to initiate a Phase 3 study of AG10 in ATTR polyneuropathy (ATTR-PN) in Q1 2020.

About transthyretin amyloidosis (ATTR)

There is significant medical need in transthyretin amyloidosis (ATTR) given the large patient population and limited current standard of care. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into three distinct categories: wild-type ATTR cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM), and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each disease is estimated to be at least 400,000 patients, 40,000 patients and 10,000 patients, respectively.

All three forms of ATTR are progressive and fatal. For patients with untreated ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in life (age 50+), with median survival of three to five years from diagnosis. ATTR-PN either presents in a patient's early 30s or later (age 50+), and results in a median life expectancy of five to ten years from diagnosis for untreated patients. Progression of all forms of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care.

About BridgeBio Pharma

BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio's pipeline of over 15 development programs includes product candidates ranging from early discovery to late-stage development. For more information, please visit http://www.bridgebio.com.

About Eidos Therapeutics

Eidos is a BridgeBio Pharma subsidiary focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing AG10, a potentially disease-modifying therapy for the treatment of ATTR. For more information, please visit http://www.eidostx.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, including the statements about the potential therapeutic and clinical benefits of AG10, the potential for AG10 to be a best-in-class treatment for ATTR-CM patients, the design of our ongoing Phase 3 ATTRibute-CM trial of AG10, our ability to enroll patients in and conduct the ATTRibute-CM trial and our planned Phase 3 clinical trial of AG10 in ATTR-PN in accordance with our plans, our ability to generate data from and to complete these trials, the timing of these events, the indications we intend to pursue and our possible clinical or other business strategies, are forward-looking statements. Forward-looking statements can be identified by terms such as "believes," "expects," "plans," "potential," "would" or similar expressions and the negative of those terms. These forward-looking statements are based on our management's current beliefs and assumptions about future events and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: our limited operating history and historical losses, our liquidity to fund the development of AG10 through current and future milestones, our ability to raise additional funding to complete the development of AG10, our dependence on the success of AG10, our ability to enroll patients in the ATTRibute-CM trial and our planned Phase 3 clinical trial of AG10 in ATTR-PN, results from our clinical trials andpre-clinicalstudies and those of third parties working in the same area as our product candidate, our ability to advance AG10 in clinical development in accordance with our plans, and our dependence on third parties in connection with our manufacturing, clinical trials andpre-clinicalstudies. Additional risks and uncertainties that could affect our future results are included in the section titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which is available on the SEC's website atwww.sec.govand our websites at eidostx.com and bridgebio.com. Additional information on potential risks will be made available in other filings that we make from time to time with the SEC. In addition, any forward-looking statements contained in this press release are based on assumptions that we believe to be reasonable as of this date. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Media Contact:Grace Rauh917-232-5478Grace.rauh@bridgebio.com

Investor Contact:John GrimaldiBurns McClellan212-213-0006jgrimaldi@burnsmc.com

See the original post here:

BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin...